Peptide Receptor Radionuclide Therapy Market Size, Share, and Industry Analysis By Radioisotope (Lutetium-177, Yttrium-90, and Others), By Type (Alpha Emitters and Beta Emitters), By Indiaction (Pancreatic NETs, Gastrointestinal (GI) tract NETs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast till 2032

The global peptide receptor radionuclide therapy (PRRT) market is growing fast due to the rising cases of neuroendocrine tumor (NET) and technological progress in the industry. According to the information released by the U.S. Food and Drug Administration (FDA), now, there are 32 FDA-approved PRRT treatment centers in America today, which demonstrate the growing clinical integration. Its effectiveness is also supported with such innovations as Lutetium-177, there are 21 registered per year clinical trials with PRRT according to ClinicalTrials.gov. It is estimated that around 2,600 patients a year in the U.S. undergo PRRT. Favorable regulatory clearances and the adoption of AI in treatment planning are the major drivers of the market growth, especially, in developed countries, where the healthcare infrastructure is highly developed.

Peptide Receptor Radionuclide Therapy Market Driver

Rising Neuroendocrine Tumor Cases Drive Demand for PRRT Treatments

An increasing number of individuals diagnosed with neuroendocrine tumors is one of the major factors that promotes the adoption of PRRT. According to the U.S. National Cancer Institute, the number of cases of NET continues to grow, which makes targeted therapies such as PRRT demanded. The impact of technological successes especially in radiopharmaceuticals like Lutetium-177 has enhanced the ability to treat the disease. The number of PRRT clinical trials in the U.S. is high annual number of trials. Market growth is also enhanced by the FDA-certification of 32 PRRT treatment centers. Also, the integration of AI in dosimetry, as noted by the U.S. National Institutes of Health, is seen to improve precision, 14 studies in the NIH portfolio being aimed at improving the advancement of PRRT.

Peptide Receptor Radionuclide Therapy Market Restraint

High Treatment Costs and Limited Infrastructure Impede PRRT Adoption

The PRRT market growth is hindered by high cost of treatment and scanty infrastructure. According to U.S. Nuclear Regulatory Commission, there are only 47 facilities licensed in the country to conduct radiopharmaceutical therapy. The FDA records 11 yearly adverse events incidences associated with PRRT, which highlights safety issues. Another area of concern is the supply chain, the NRC reports that the United States imports 15,000 curies worth of PRRT-associated isotopes per year as domestic supply fails to meet production. Moreover, a lack of specialized personnel is observed, and only 480 certified nuclear medicine technologists work in PRRT according to the Nuclear Medicine Technology Certification Board (NMTCB). The convergence of these elements limits the wider access to markets.

Peptide Receptor Radionuclide Therapy Market Opportunity

Emerging Regions Offer Strong Growth Potential for PRRT Adoption

Newer areas have high potential of PRRT growth. The International Atomic Energy Agency argues that, there are 17 annual PRRT training workshops held in Asia pointing out that there is increasing expertise. The European adoption is also high with 42 centers approved by the European Medicines Agency. Progress in the design of new therapies, for instance Lutetium-177 NeoBOMB1, may widen the usage beyond NETs. There is also an additional contribution to efficacy by combination therapies with chemotherapy or immunotherapy. According to the IAEA there are six Lutetium-177 reactors currently operating in Asia Pacific that are used to make radiopharmaceuticals. Such tendencies demonstrate the potential of unexplored phenomena of developing healthcare markets.

Segmentation

Key Insights

The report covers the following key insights:

• Key Industry Trends
• Regulatory Landscape across Key Regions
• Key Industry Developments
• Growth Opportunities in Emerging Markets

Analysis By Radioisotope

By Radioisotope, the Peptide Receptor Radionuclide Therapy Market is divided into Lutetium-177, Yttrium-90 & Others. 

Lutetium-177 is market leader as it has been widely used in the FDA-approved therapies and the clinical trials. As the U.S. FDA data indicate, the number of clinically explored Lutetium-177-based therapy gradually increases, with 21 clinical experiments that include PRRT being held every year in the United States. The segment should be able to sustain its leadership due to its effectiveness and safety profile.

Analysis By Type

By Type, the Peptide Receptor Radionuclide Therapy Market is divided into Alpha Emitters, Beta Emitters. 

The market is dominated by Beta emitters as they are already used in PRRT. The segment is expected to expand to a considerable degree, supported by the innovation in radiopharmaceuticals and the growth in use in clinical practices.

Analysis By Indiaction

By Indiaction, the Peptide Receptor Radionuclide Therapy Market is divided into Pancreatic NETs, Gastrointestinal (GI) tract NETs & Others. 

NETs affecting the gastrointestinal (GI) track are associated with significant growth considering the high rates of the condition and the rising number of diagnoses. Data presented by the U.S. National Cancer Institute indicate that GI tract NETs represent a large share of the PRRT application, which creates demand of targeted therapy.

Analysis By Distribution Channel

By Distribution Channel, the Peptide Receptor Radionuclide Therapy Market is divided into Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies. 

The market also consists of hospital pharmacies as the administration of PRRT mostly happens in dedicated healthcare facilities. The market is facilitated by the fact that the U.S. boasts of 32 FDA-approved centers of PRRT treatment, as stated by the FDA.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on geography, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

According to the United States Food and Drug Administration, North America captures a slow portion of the global PRRT market share pegged at around 40%. The geographical momentum is motivated by the developed healthcare system, the strong uptake of innovative treatments, and favorable regulations. The National Cancer Institute estimated 2,600 patients are currently treated with PRRT in the U.S. each year, and 32 FDA-approved treatment centers exist countrywide. Research is continuing clinically, where 21 trials in PRRT continue per year. Nonetheless, the current dependence on foreign imports of isotopes (15,000 Ci/year, according to NRC) puts into focus the vulnerabilities in the supply chain, and this issue might need to be addressed to achieve long-term growth.

According to the European Medicines Agency, the proportion of the market share Europe has in PRRT is 35 percent. The area enjoys positive reimbursement policy, robust cancer research programs, and the availability of treatment and 42 approved EMA PRRT center facilities. Germany is a leader in clinical implementation 65 hospitals are implementing PRRT according to Federal Statistical Office of Germany. There is a large degree of research activity, with 19 active clinical trials registered in the EU Clinical Trials Register. The Netherlands is a major supplier of isotopes as they export 21,000 Ci of Lutetium-177 yearly reported in National Institute for Public Health and the Environment.

Asia Pacific witnesses the fastest growth in the market of PRRT supported by the increasing incidence of cancer and better healthcare infrastructure. The International Atomic Energy Agency attests to the 17 yearly PRRT training workshops to be held in the region, with expertise on the rise. India has 26 hospitals approved by PRRT as per Bureau of Indian Standards, whereas China has 22 regulated manufacturing premises as per National Medical Products Administration. Japan is also a real powerhouse in research: 13 nuclear medicine trials using PRRT take place yearly in the country. The government also supports the research in South Korea as the country invests 11 million each year in PRRT research. Nevertheless, a growing number of scientific publications (31 annually, according to the National Science and Technology Commission of China) show a higher interest in the regional development of PRRT use.

Key Players Covered

The report includes the profiles of the following key players:

• Novartis AG (Switzerland)
• Isotope Technologies Munich SE (Germany)
• 3B Pharmaceuticals GmbH (Germany)
• Lantheus (U.S.)
• Curium (France)
• Orano Med (France)

Key Industry Developments

• In March 2025, the U.S. FDA expanded the use of Lu-PSMA-617 for treating prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.